BusinessWire

Appointment of John Vandemore as Chief Financial Officer Allows
David Weinberg to Continue Focusing on Global Growth as Chief Operating
Officer

Motel 6 and Studio 6 Top Performers Recognized at Brand Convention

Customer adoption triples over prior year, showcasing demand for the
world’s first Operating System for the Digital Workforce

Strong Q3 and YTD revenue performance and cash position contribute to
recent company debt repricing, and well-positions company for strategic
innovation opportunities and continued operational success

Acquisition of the Livermore, Calif.-based office equipment dealer
marks a return to strategic acquisitions by TABS

Heightened fulfillment requirements transform expectations as
two-thirds of shoppers prefer next-or same-day delivery

The Seventh Annual State of Women-Owned Businesses Report,
Commissioned by American Express OPEN Finds There are 114% More
Women-Owned Businesses in the U.S. Than 20 Years Ago

Number of Firms Owned by Women of Color Has Grown by 467% Over the
Past 20 Years

RPA industry expert Richard Denton appointed as Symphony’s UiPath
practice lead

ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune”) a biopharmaceutical
company developing novel therapeutic agents for the treatment of
immunologic and inflammatory diseases, today announced financial results
for the quarter ending September 30, 2017 and provided a corporate
update.

Third Quarter 2017 and Recent Highlights

HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first
commercial launch of FOTIVDA® (tivozanib) with the initiation
of product sales in Germany. In the European Union, Norway and Iceland,
tivozanib is indicated for the first line treatment of adult patients
with advanced renal cell carcinoma (aRCC) and for adult patients who are
vascular endothelial growth factor receptor (VEGFR) and mTOR pathway

Pages